Advances in antithrombin therapy for ST-elevation myocardial infarction

Chinese Medical Journal

Volumn 116, Issue 11, 2003, Pages 1760-1763

  Chen, Wai Hong ^a   Lau, Chu Pak ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Antithrombotic therapy; Myocardial infarction; Thrombin

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PROCOAGULANT; STREPTOKINASE; TENECTEPLASE; THROMBIN; THROMBIN INHIBITOR; THROMBOCYTE FACTOR 4; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING DISORDER; BRAIN HEMORRHAGE; CLINICAL PRACTICE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG SAFETY; FIBRINOLYSIS; HEART REINFARCTION; HUMAN; MEDICAL DECISION MAKING; REVIEW; RISK BENEFIT ANALYSIS; ST SEGMENT ELEVATION; STANDARD;

ANTICOAGULANTS; ELECTROCARDIOGRAPHY; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MYOCARDIAL INFARCTION; THROMBIN;

EID: 0348156863     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1992; 339:753-770.
2. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
3. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both in coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622.
4. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999;100:1016-1030.
5. Collins R, MacMahon S, Flather M, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction treated with thrombolytic therapy. Br Med J 1996;313:652-659.
6. The International Study Group. In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between tissue plasminogen activator or streptokinase with or without heparin. Lancet 1990;336:71-75.
7. Hsia J, Hamilton WP, Kleiman N, et al. for the Heparin-Aspirin Reperfusion Trial {HART} Investigators. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990;323:1433-1437.
8. Bleich SD, Nichols T, Schumacher R, et al. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:1412-1417.
9. Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994;90:1522-1536.
10. Antman E, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition In Myocardial Infurction (TIMI) 9A Trial. Circulation. 1994;90:1624-1630.
11. Neuhaus KL, von Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study: A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALK). Circulation 1994;90:1638-1642.
12. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) II a Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631-1637.
13. Simes RJ, Granger CB, Antman EM, et al. Impact of hirudin versus heparin on mortality and (re) infarction in patients with acute coronary syndromes: a prospective meta-analysis of the GUSTO-II b and TIMI 9B trials. Circulation 1996;94:I1-I430.
14. White HD, Aylward PE, Frey MJ, et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997;96:2155-2161.
15. The Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001;358:1855-1863.
16. Klein W, Buchwald A, Hillis SE, et al. Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997;96:61-68.
17. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337: 447-452.
18. Antman EM, McCabe CH, Gurfinkel EP, et al, for the TIMI (Thrombolysis In Myocardial Infarction) 11B Investigators. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B Trial. Circulation 1999;100:1593-1601.
19. FRAXIS study group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction: FRAXIS (FRAXiparine in Ischaemic Syndrome). Eur Heart J 1999;20:1553-1562.
20. Ross AM, Molhoek P, Lundergan C, et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin. Circulation 2001;104:648-652.
21. Simoons ML, Alonso A, Krzeminska-Pakula M, et al. Early ST segment elevation resolution: predictor of outcome and angiographic patency inpatients with acute myocardial infarction. Results of the AMI-SK study. Eur Hear t J (in press).
22. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358:605-613.